EndoBarrier Therapy

The first endoscopically delivered device therapy for obese patients with type 2 diabetes.

A paradigm shift in metabolic control with three clinical effects:

Restores healthy glycemic levels

Mean Hba1c decreased from 8.5% at baseline to 6.7 % after three months and remained relatively steady throughout the 12-month treatment. ª

Potentially improves cardio metabolic risk factors

Interrupts the chronic progression of type 2 diabetes and obesity and has been shown to improve cardio metabolic risk factors. ¹ ² ³ º

Produces significant weight loss

Patients lost up to 20% of their body weight at 1 year. ²

1,2,3,4,5 references detailed below

Click here to view the EndoBarrier Patient Profiles.


Referral Centres

Do you know where to refer patients to?

Well established specialist centres in the UK are currently treating patients with the EndoBarrier Therapy.

Click here to view contact the details.

Latest News

  • Could the EndoBarrier be the solution to the UK Diabetes crisis (more)
  • Success story: 2 stone weight loss and substantial reduction in medication (more)
  • EndoBarrier shows reduction in cardio risk (more)
  • EndoBarrier Therapy reduces reliance on diabetes medication (more)
  • EndoBarrier eliminates or reduces insulin therapy (more)

NHS Hospitals

The REVISE-Diabesity study is supported by the NHS as one of the National Institute for Health Research (NIHR) Clinical (Diabetes) Research Network Portfolio Studies. The study is open at:

  • Birmingham's City Hospital
  • London's King's College Hospital
  • Glasgow Royal Infirmary

Read more here ... 

Contact us on 0844 412 0020 or

info@elementalhealthcare.co.uk to find out more.

Click on the image to view the EndoBarrier animation.

1. Moura EG, et al. Metabolic improvements in obese
 type 2 diabetes subjects implanted for 1 year with an
 endoscopically deployed duodenal-jejunal bypass liner. 
Diabetes Technol Ther 2012;14(2):183-189. 
2. Escalona A, et al. Weight loss and metabolic 
improvement in morbidly obese subjects implanted for 
1 year with an endoscopic duodenal-jejunal bypass liner. 
Ann Surg 2012;255(6):1080-1085
3. Cohen, R., et. al. Role of proximal gut exclusion from 
food on glucose homeostasis in patients with Type 2 
diabetes. Diabet Med. 2013;30 (12):1482-6. 
O. Chilton, R., et. al., Endoscopic, Duodenal-Jejunal 
Bypass Liner in Obese Patients with or without Type 2 
Diabetes Lowers Incidence of Metabolic Syndrome and 
Improves Cardiovascular Risk. Poster presentation, 
EASD 2014, Vienna, Austria. 
a. Data on file (GI Dynamics, Inc.)


« Back to News

Latest News

Well done Team!

Customer Satisfaction Survey 2019: THE RESULTS

Continue Reading